Multiple intracellular pathways

Multiple intracellular pathways is a descriptive term rather than a specific molecular target, referring to the collective modulation of various signaling cascades within a cell. This term is frequently used in the context of multi-target drugs, such as multi-kinase inhibitors, which exert their therapeutic effects by interacting with several different enzymes or receptors simultaneously (Hopkins, A. L., Nature, 2008). These pathways often include the MAPK/ERK, PI3K/Akt/mTOR, and JAK/STAT signaling routes, which are critical for regulating cell growth, differentiation, and survival (Knight, Z. A., et al., Nature Reviews Cancer, 2010). In diseases like cancer, targeting multiple pathways can help overcome drug resistance and improve clinical outcomes by blocking redundant survival signals (Wilhelm, S. M., et al., Nature Reviews Drug Discovery, 2006). However, because this term lacks a specific molecular identity, it is generally classified as an incorrect or non-specific target entry in structured pharmacological databases. It represents a shift from the one gene, one drug, one disease paradigm toward a systems-biology approach to drug discovery. Biotech analysts should recognize this entry as a placeholder for polypharmacology rather than a single druggable protein.

Other names

Multiple signaling pathwaysIntracellular signaling cascadesPolypharmacological targets

Simultaneous inhibition or modulation of multiple intracellular signaling proteins and cascades to disrupt disease-driving networks.